Literature DB >> 31587314

An Optical Surface Applicator for Intraoperative Photodynamic Therapy.

Sarah Chamberlain1, David Bellnier1, Sai Yendamuri2, Joerg Lindenmann3, Todd Demmy2, Chukwumere Nwogu2, Max Ramer1, Larry Tworek1, Emily Oakley1, Matthew Mallory1, Lindsey Carlsen1, Sandra Sexton4, Leslie Curtin4, Gal Shafirstein1.   

Abstract

BACKGROUND AND OBJECTIVES: Intraoperative photodynamic therapy (IO-PDT) is typically administered by a handheld light source. This can result in uncontrolled distribution of light irradiance that impacts tissue and tumor response to photodynamic therapy. The objective of this work was to characterize a novel optical surface applicator (OSA) designed to administer controlled light irradiance in IO-PDT. STUDY DESIGN/
MATERIALS AND METHODS: An OSA was constructed from a flexible silicone mesh applicator with multiple cylindrically diffusing optical fibers (CDF) placed into channels of the silicone. Light irradiance distribution, at 665 nm, was evaluated on the OSA surface and after passage through solid tissue-mimicking optical phantoms by measurements from a multi-channel dosimetry system. As a proof of concept, the light administration of the OSA was tested in a pilot study by conducting a feasibility and performance test with 665-nm laser light to activate 2-(1'-hexyloxyethyl) pyropheophorbide-a (HPPH) in the thoracic cavity of adult swine.
RESULTS: At the OSA surface, the irradiance distribution was non-uniform, ranging from 128 to 346 mW/cm2 . However, in the tissue-mimicking phantoms, beam uniformity improved markedly, with irradiance ranges of 39-153, 33-87, and 12-28 mW/cm2 measured at phantom thicknesses of 3, 5, and 10 mm, respectively. The OSA safely delivered the prescribed light dose to the thoracic cavities of four swine.
CONCLUSIONS: The OSA can provide predictable light irradiances for administering a well-defined and potentially effective therapeutic light in IO-PDT. Lasers Surg. Med.
© 2019 Wiley Periodicals, Inc. © 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  intraoperative photodynamic therapy; non-small-cell lung cancer; optical tissue-mimicking phantom

Mesh:

Substances:

Year:  2019        PMID: 31587314      PMCID: PMC7131890          DOI: 10.1002/lsm.23168

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092


  25 in total

1.  Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer.

Authors:  Emily Oakley; David A Bellnier; Alan Hutson; Brian Wrazen; Hassan Arshad; Harry Quon; Gal Shafirstein
Journal:  Lasers Surg Med       Date:  2017-02-10       Impact factor: 4.025

2.  Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a; HPPH) for photodynamic therapy.

Authors:  David A Bellnier; William R Greco; Hector Nava; Gregory M Loewen; Allan R Oseroff; Thomas J Dougherty
Journal:  Cancer Chemother Pharmacol       Date:  2005-11-05       Impact factor: 3.333

3.  Definitive surgery and intraoperative photodynamic therapy: a prospective study of local control and survival for patients with pleural dissemination of non-small cell lung cancer.

Authors:  Charles B Simone; Keith A Cengel
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2014-03-18

4.  Illumination profile characterization of a light device for the dosimetry of intra-pleural photodynamic therapy for mesothelioma.

Authors:  Camille Munck; Serge Mordon; Nacim Betrouni
Journal:  Photodiagnosis Photodyn Ther       Date:  2016-09-01       Impact factor: 3.631

5.  Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.

Authors:  B W Henderson; T M Busch; L A Vaughan; N P Frawley; D Babich; T A Sosa; J D Zollo; A S Dee; M T Cooper; D A Bellnier; W R Greco; A R Oseroff
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

6.  Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.

Authors:  Joseph S Friedberg; Charles B Simone; Melissa J Culligan; Andrew R Barsky; Abigail Doucette; Sally McNulty; Stephen M Hahn; Evan Alley; Daniel H Sterman; Eli Glatstein; Keith A Cengel
Journal:  Ann Thorac Surg       Date:  2016-11-05       Impact factor: 4.330

Review 7.  Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions.

Authors:  Gal Shafirstein; Athar Battoo; Kassem Harris; Heinz Baumann; Sandra O Gollnick; Joerg Lindenmann; Chukwumere E Nwogu
Journal:  Ann Am Thorac Soc       Date:  2016-02

8.  Photodynamic therapy with 3-(1'-hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity.

Authors:  Nestor Rigual; Gal Shafirstein; Michele T Cooper; Heinz Baumann; David A Bellnier; Ulas Sunar; Erin C Tracy; Daniel J Rohrbach; Gregory Wilding; Wei Tan; Maureen Sullivan; Mihai Merzianu; Barbara W Henderson
Journal:  Clin Cancer Res       Date:  2013-10-02       Impact factor: 12.531

9.  Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors.

Authors:  Barbara W Henderson; Sandra O Gollnick; John W Snyder; Theresa M Busch; Philaretos C Kousis; Richard T Cheney; Janet Morgan
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  Irradiance controls photodynamic efficacy and tissue heating in experimental tumours: implication for interstitial PDT of locally advanced cancer.

Authors:  Gal Shafirstein; David A Bellnier; Emily Oakley; Sasheen Hamilton; Michael Habitzruther; Lawrence Tworek; Alan Hutson; Joseph A Spernyak; Sandra Sexton; Leslie Curtin; Steven G Turowski; Hassan Arshad; Barbara Henderson
Journal:  Br J Cancer       Date:  2018-10-24       Impact factor: 7.640

View more
  1 in total

1.  TLD1433-Mediated Photodynamic Therapy with an Optical Surface Applicator in the Treatment of Lung Cancer Cells In Vitro.

Authors:  Sarah Chamberlain; Houston D Cole; John Roque; David Bellnier; Sherri A McFarland; Gal Shafirstein
Journal:  Pharmaceuticals (Basel)       Date:  2020-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.